Abstract Number: 090 • 2023 Pediatric Rheumatology Symposium
Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience
Background/Purpose: The management of pediatric rheumatic disease has been forever changed by the advent of biologic drugs and the pursuit of targeted therapy. There is…Abstract Number: 183 • 2020 Pediatric Rheumatology Symposium
Collaboration Between Rheumatology Clinic and Specialty Pharmacy to Positively Impact Patient Experience and Hospital Stewardship
Background/Purpose: Biologic medications are commonly utilized to treat pediatric rheumatic diseases. Being high-cost, most third-party payors require dispensing through a specialty pharmacy. Common challenges with…Abstract Number: L12 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…Abstract Number: L13 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…Abstract Number: L17 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…Abstract Number: 1498 • 2019 ACR/ARP Annual Meeting
A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine…Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…Abstract Number: 1504 • 2019 ACR/ARP Annual Meeting
Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60%…Abstract Number: 2399 • 2019 ACR/ARP Annual Meeting
Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis
Background/Purpose: During the past 15 years, advancements in the understanding of the safety and effectiveness, as well as the expanding access and availability of biologic…Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting
Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…Abstract Number: 2505 • 2019 ACR/ARP Annual Meeting
Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in…Abstract Number: 1520 • 2019 ACR/ARP Annual Meeting
Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status
Background/Purpose: Long-term real-world treatment patterns of psoriasis patients are not well characterized, especially those with comorbid psoriatic arthritis (PsA). This study examined the treatment patterns…Abstract Number: 2544 • 2019 ACR/ARP Annual Meeting
Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE
Background/Purpose: Belimumab is approved as add-on therapy in active, autoantibody-positive SLE. Safety and efficacy up to 13 years has been reported in adults, but potential…Abstract Number: 71 • 2019 ACR/ARP Annual Meeting
Inhibition of Nuclear Pore Export Ameliorates Lupus via Modulation of Plasma Cell Generation and Survival
Background/Purpose: A major challenge in lupus is the elimination of autoreactive plasma cells, which amplify inflammation at peripheral sites via deposition of autoantibody-self antigen complexes.…Abstract Number: 1522 • 2019 ACR/ARP Annual Meeting
Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks
Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease involving the axial skeleton; inflammatory bowel disease (IBD) and acute anterior uveitis (AAU) are common…
- 1
- 2
- 3
- …
- 29
- Next Page »